Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. reports developments in commercial-stage cancer prevention diagnostics for patients with gastroesophageal reflux disease who are at risk for esophageal precancer and esophageal adenocarcinoma. The company, a subsidiary of PAVmed Inc., markets the EsoGuard Esophageal DNA Test and uses the EsoCheck Esophageal Cell Collection Device to collect samples through a brief, noninvasive office procedure.
Recurring updates cover EsoGuard commercialization, healthcare-system access, clinical evidence for esophageal precancer detection, quarterly business results, cash resources, and conference presentations. Lucid news also includes capital actions such as registered common stock offerings and related use of proceeds for working capital and general corporate purposes.
Lucid Diagnostics (Nasdaq: LUCD) reported second quarter 2026 EsoGuard revenue of $1.474 million, up from $1.163 million in 2Q25, and processed 2,770 EsoGuard Esophageal DNA Tests. The company highlighted strengthening commercial activity, including its first laboratory benefit manager coverage policy via Concert, now part of Lyric, adopted by multiple client health plans.
For the quarter ended June 30, 2026, Lucid recorded operating expenses of $14.3 million and a GAAP net loss of $11.7 million, with net loss attributable to common stockholders of $14.7 million, or $(0.08) per share. Non-GAAP adjusted loss was $10.9 million, or $(0.06) per share. Lucid held $33.4 million in cash and cash equivalents at June 30, 2026, compared with $34.7 million at December 31, 2025, and reported EBITDA of $(11.5) million. The company also developed a health economic cost-effectiveness model to support payor engagement for EsoGuard.
Lucid Diagnostics (Nasdaq: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive commercial coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer.
The policy cites sufficient evidence in guidelines and peer-reviewed literature to demonstrate improved health outcomes and deems Lucid’s EsoGuard Esophageal DNA Test medically necessary for patients who meet American College of Gastroenterology (ACG) screening criteria. According to Lucid, multiple Concert client health plans have already adopted this policy, supporting broader commercial access to EsoGuard and reinforcing the company’s clinical evidence base.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), will participate in two investor events: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026 and the Canaccord Genuity 46th Annual Growth Conference fireside chat on August 11, 2026 at 11:30 AM ET in Boston, MA. The Canaccord fireside chat will be available via live and archived webcast through the Investor Relations section of the Lucid Diagnostics website, with a replay accessible for 30 days after the live broadcast.
PAVmed (Nasdaq: PAVM) announced it will host a second quarter 2026 business update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. CEO Lishan Aklog will discuss business operations and growth strategy, and President/CFO Dennis McGrath will review second quarter 2026 financial results.
Lucid Diagnostics (Nasdaq: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), will host a second quarter 2026 business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. Management will review business operations, growth strategy, and second quarter 2026 financial results. The live webcast and a 30-day replay will be available in the investor relations section of luciddx.com, with telephone access for U.S. and international callers.
PAVmed (NASDAQ:PAVM) reported Q1 2026 results and a business update spanning Lucid Diagnostics (NASDAQ:LUCD) and Veris Health. Revenue was $22 thousand, operating expenses $8.1 million, and GAAP net loss attributable to common stockholders about $7.0 million or $(4.42) per share. Non-GAAP adjusted net loss was $1.9 million or $(1.17) per share. Cash and equivalents rose to $6.5 million from $1.5 million at year-end. Lucid recognized $1.3 million in EsoGuard revenue on 3,177 tests and raised roughly $17 million, ending with $45 million pro forma cash and runway into 2027. Veris advanced its implantable physiological monitor toward a planned FDA 510(k) submission and expanded its commercial engagement with OSU-The James.
Lucid Diagnostics (Nasdaq: LUCD) reported first quarter 2026 results and a business update. The company processed 3,177 EsoGuard tests and generated $1.256 million in revenue, with operating expenses of $13.4 million and GAAP net loss of $13.9 million, or $(0.17) per share.
Non-GAAP adjusted loss was $10.5 million. An underwritten equity offering added about $17 million, supporting $45 million in proforma cash and runway into 2027. Management highlighted efforts toward Medicare coverage, expanded payer and health system engagement, and a strong presence at DDW with EsoGuard clinical data and guideline visibility.
PAVmed (Nasdaq: LUCD) will host a First Quarter 2026 business update conference call and webcast on May 15, 2026 at 8:30 AM ET. CEO Lishan Aklog will provide a business update and CFO Dennis McGrath will discuss Q1 2026 financial results.
Investors can join via webcast at the investor relations page on pavmed.com or by telephone (U.S. 1-800-836-8184; international 1-646-357-8785). A replay will be available on pavmed.com for 30 days after the call.
Lucid Diagnostics (Nasdaq: LUCD) will host a business update conference call and webcast on Thursday, May 14, 2026 at 8:30 AM ET. CEO Lishan Aklog will provide a business update and CFO Dennis McGrath will discuss first quarter 2026 financial results.
The live webcast and a 30-day replay will be available on the company's investor relations website at luciddx.com. Telephone access is available for U.S. and international listeners with provided dial-in numbers; attendees should reference the conference call name "Lucid Diagnostics Business Update."
Lucid Diagnostics (NASDAQ: LUCD) closed an underwritten registered direct offering of 18,000,000 common shares at $1.00 per share, generating approximately $18 million in gross proceeds on April 24, 2026.
The offering was anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. Net proceeds are intended for working capital and general corporate purposes.